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Abstract  
 
There is a desperate need for new and effective therapeutic approaches for AML in 
both children and adults. Epigenetic aberrations are common in adult AML, and many 
novel epigenetic compounds are in clinical development that may improve patient 
outcomes. Mutations in epigenetic regulators occur less frequently in AML in 
children compared to adults. However, investigating the potential benefits of 
epigenetic therapy in paediatric AML is an important issue that will be discussed in 
this review. 
 
Introduction 
 
Acute myeloid leukaemia (AML) results from clonal expansion of primitive myeloid 
cells that are incapable of differentiation. These clones have acquired genetic and 
epigenetic alterations that cause uncontrolled proliferation at the expense of normal 
haematopoiesis, leading to bone marrow exhaustion. The recent identification and 
characterisation of many of these alterations (Papaemmanuil et al. 2016) creates the 
opportunity for the development of targeted treatments. Cancer genome consortiums 
have identified genes commonly mutated in AML, many of which are associated with 
epigenetic regulation (Genovese et al. 2014; Jaiswal et al. 2014; Xie et al. 2014; The 
Cancer Genome Atlas Research Network 2013a), indicating that chromatin modifiers 
play key roles in malignant transformation and exposing novel epigenetic targets for 
cancer drug discovery. Whilst there are biological, molecular and clinical distinctions 
between adult and paediatric AML, therapies tested in adult patients in clinical trials 
have often been extrapolated across the age spectrum and used in paediatrics with 
clinical benefit. Epigenetic therapy has become an important area of research with 
many novel compounds being tested in adult AML; it is therefore pertinent to 
examine those that may be of benefit in children. This review will summarise the 
epigenetic landscape of adult and paediatric AML, the progress to date in epigenetic 
therapies for adult AML and finally their potential benefit in childhood AML.  
AML is the most common acute leukaemia, affecting 3 out of every 100000 people in 
the UK (Cancer Research UK). The risk of developing AML is age-associated, with 
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the incidence rising from 7 cases per million per year in children to 170 cases per 
million per year in adults over 60 years (Cancer Research UK). There is a desperate 
and urgent need for better therapies for both children and adults with AML. Survival 
rates have remained low in adults (overall survival (OS) 20% at 5 years (Cancer 
Research UK); and although survival rates are higher in children (OS 70% at 5 years), 
intensive chemotherapy regimens are burdensome and relapsed/refractory AML 
account for half of childhood leukaemia related deaths (Moore et al. 2013). Whilst the 
last few decades have seen an improvement in survival of children with AML, this 
has been due to a combination of a more strategic use of stem cell transplantation and 
better supportive care reducing treatment and transplant related mortality (Kaspers et 
al. 2013; Perel et al. n.d.; Burnett et al. 2013; Gibson et al. 2011; Stevens et al. 1998). 
There have been very few new drugs that have brought benefit to patients and relapse 
remains the main cause of death. Epigenetic therapies may bring benefit by reducing 
relapse, however it is important that their toxicity profile be clarified as this may be 
different in children than adults.  
 
Epigenetic landscape of AML 
 
Epigenetics describes how heritable changes to gene expression can occur in the 
absence of any change to the underlying DNA sequence (Egger et al. 2004). The 
epigenetic landscape controls gene expression through a variety of chromatin 
modifications, for example DNA methylation and histone post-translation 
modifications. Some of these modifications alter the accessibility of DNA to 
transcriptional machinery; others enable chromatin mediated signal transduction or 
the direct recruitment of DNA replication machinery. Epigenetic dysfunction is 
common to most cancers (Jones & Baylin n.d.; Sharma et al. 2010). Compared to 
other cancer types AML has few mutations (The Cancer Genome Atlas Research 
Network 2013a) and as mentioned, many of these mutations affect the epigenome. 
This finding illustrates the importance of epigenetic regulation in normal 
haematopoiesis, and importantly, opens up the potential for a plethora of novel targets 
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in cancer therapy. Mechanisms of epigenetic deregulation have been widely studied in 
AML and the most frequently occurring will be briefly summarised below. 
 
Aberrant DNA methylation 
Disordered methylation patterns are a hallmark of AML (The Cancer Genome Atlas 
Research Network 2013a; Figueroa, Lugthart, et al. 2010) and have been implicated 
in gene silencing of tumour suppressor genes and genomic instability. More recent 
work has implicated both hyper-and hypo-methylation in malignant transformation 
(Akalin et al. 2012; Berman et al. 2011). Intriguingly, these methylation signatures 
have prognostic relevance and can distinguish between subtypes of AML, indicating a 
causal role of aberrant methylation in AML (Saied et al. 2012; Figueroa, Lugthart, et 
al. 2010). DNA methylation is established by DNA methyl transferases (DNMTs). 
DNMT3a is a de novo methyl transferase that regulates DNA methylation and is one 
of the most frequently mutated genes in adult AML (Ley et al. 2010), highlighting the 
importance of methylation patterns for normal haematopoiesis and AML 
pathogenesis. Mutations in DNMT3a have been found in paediatric AML at lower 
frequencies (1-2% versus 20-22%, respectively; see table 1). DNMT3a mutations in 
AML are predominately heterozygous R882H, (Yang et al. 2015) and are dominant-
negative, inhibiting wild type DNMT3A (Russler-Germain et al. 2014). In vivo work 
suggests the mutation confers increased self renewal, impaired differentiation and a 
repopulation advantage over wildtype haematopoietic stem cells (HSCs) (Challen et 
al. 2011), although additional co-operating mutations are required to give rise to AML 
(Mayle et al 2015). Importantly, DNMT3a mutations can confer resistance to 
chemotherapy, giving rise to a population of cells primed for relapse (Guryanova et 
al. 2016; Shlush et al. 2014). Although our understanding of the relationship between 
DNMT3A mutations, DNA methylation and AML is still incomplete, targeting 
DNMT3a mutations could be a highly attractive treatment approach, particularly as 
this abnormality confers a poor outcome (Ley et al. 2010).  
Ten-eleven translocation 2 (TET2) mutations represent another pathway to aberrant 
DNA methylation. TET2 oxidises 5-methylcytosine (5-MC) to 5-
hydroxymethylcytosine (5-HMC), leading to DNA demethylation and reversal of 
methylation-driven gene silencing (Li et al. 2011). TET2 is commonly mutated in 
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adult AML (8-23%; see table 1) (The Cancer Genome Atlas Research Network 
2013a; J. P. Patel et al. 2012; Abdel-Wahab et al. 2009), however these mutations are 
rare in paediatric AML (1.7%; see table 1) (Liang et al. 2013). It was hypothesised 
that TET2 regulated HSC self-renewal. In support of this, TET2 knock-out HSCs 
undergo expansion in vivo and outcompete wild type HSCs in serial transplantation 
assays (Li et al. 2011; Moran-Crusio et al. 2011). In a mouse model of AML and also 
in primary human patient samples, loss of TET2 caused DNA hypermethylation at 
active enhancers; this was associated with down regulation of tumour suppressor 
genes (for example, Mtss1, Las2, Lxn, Ctdsp1 and Grap2) and up regulation of 
oncogenes, including Notch3 and Igf1r (Rasmussen et al. 2015). Collectively, these 
studies suggest that, similar to other epigenetic mutations such as DNMT3a, TET2 
loss leads to aberrant DNA methylation, increased HSC self-renewal and impaired 
differentiation, and contributes to leukaemia.    
 
Isocitrate dehydrogenase 1/2 (IDH1/2) catalyse the conversion of isocitrate to alpha-
ketoglutarate (α-KG), a co-factor required by TET2 for conversion of 5-MC to 5-
HMC and subsequent DNA demethylation (Ward et al. 2010; Dang et al. 2009). 
IDH1/2 are also frequently mutated in AML (5-33%; see table 1), and are mutually 
exclusive with TET2 mutations (The Cancer Genome Atlas Research Network 2013b; 
Marcucci et al. 2010). IDH1/2 mutations have been found in paediatric AML at lower 
frequencies than adult AML (1-4%, see table 1) (Valerio et al. 2014; Liang et al. 
2013; Damm et al. 2011a). Mutations in IDH1/2 lead to both loss and gain of 
function; cells harbouring these mutations are unable to catalyse α-KG, and instead 
neomorphically synthesise the oncometabolite 2-hydroxyglutarate (2-HG). Elevated 
2-HG leads to aberrant DNA methylation. Work by Figueroa et al has shown that 
IDH1/2 mutations in AML induce hypermethylation, particularly at promoter regions, 
and this is associated with impaired differentiation and upregulation of a HSC gene 
expression profile (Figueroa, Abdel-Wahab, et al. 2010). 
Mutations in ASXL1/2 
Addition of sex-combs like 1/2 (ASXL1/2) is a member of the polycomb repressor 
complex 2 (PRC2) and is mutated in adult and paediatric AML at various frequencies 
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(3-15% versus 1-9% respectively; see table 1). ASXL1 recruits PRC2 to its target loci 
and is required for maintenance of H3K27me3. Knock-down of ASXL1 in vitro in a 
human AML cell line resulted in a global loss of H3K27me3 that correlated with an 
increase in HOX gene expression; interestingly, this transcriptional profile was 
strongly enriched for a gene expression signature associated with both MLL-AF9 and 
NUP98-HOXA9-expressing bone marrow cells (Abdel-Wahab et al. 2012), indicating 
ASXL1 mutations impair PRC function and promote myeloid malignancies by 
induction of HOX gene expression programs. Other gene mutations that impair PRC 
function have been discovered in AML, for example EZH2, SUZ12, EED, JARID2. 
This demonstrates the importance of this complex in haematopoiesis and myeloid 
malignancies (Score et al. 2012; Abdel-Wahab et al. 2011).There is a strong 
correlation between mutations in ASXL1 and advanced age (>60 years) (Schnittger et 
al. 2012; Metzeler et al. 2011). In a paediatric cohort, 8.8% (18/204 AML patients) 
had ASXL1/2 mutations, suggesting these occur less frequently than in adult 
populations (Shiba et al. 2016). However, the authors found a strong association 
between ASXL1/2 mutations and t(8;21) AML in the paediatric cohort, (20%, similar 
to that of adult cohorts), highlighting the need for improved patient stratification for 
epigenetic therapy, particularly in paediatric patients in whom epigenetic mutations 
are rare yet maybe enriched and therefore targetable in certain patient subgroups.  
Histone acetylation  
Histone acetylation is an important regulator of gene expression, governed by two 
opposing enzymes, lysine acetyl transferases (KATs) and histone deacetylases 
(HDACs). Histone acetylation weakens the interaction between DNA and histones, 
resulting in an open chromatin conformation, therefore KATs are gene activators. 
KAT rearrangements, but not mutations, have been identified in AML at 
exceptionally low frequencies (The Cancer Genome Atlas Research Network 2013a; 
Wouters & Delwel 2016; Rozman et al. 2004). HDACs remove acetyl groups from 
histones, leading to chromatin compaction and gene inactivation. Mutations in 
HDACs are extremely rare in AML (The Cancer Genome Atlas Research Network 
2013a; Wouters & Delwel 2016). However, HDACs can be aberrantly recruited by 
leukaemia-associated fusions (such as PML-RARA, EVI1 and AML/ETO) to shut 
down differentiation gene expression programs and maintain the AML phenotype. 
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This highlights their attractiveness as therapeutic targets in AML (Grignani et al. 
1998; Izutsu et al. 2001; Fazi et al. 2007; Fong et al. 2014).   
 
MLL-translocations 
 
Mixed lineage leukaemia (MLL-leukaemia) is characterised by chromosomal 
translocations affecting the MLL gene and its binding partners, most commonly 
ALL1-fused gene from chromosome 9 (AF9) (Slany 2009). In AML, MLL fusion 
proteins recruit a histone methyl transferase (HMT), DOT1, resulting in aberrant 
methylation of H3K79 at MLL gene targets and enhanced expression of leukaemia-
associated genes (Slany 2009). MLL translocations occur more frequently in 
paediatric than adult AML (30-50% versus >10%, respectively) (Chaudhury et al. 
2015; Krivtsov & Armstrong 2007; Schoch 2003; Grimwade et al. 1998), and are the 
most common aberration in infant AML (Harrison et al. 2010). There is a strong 
rationale for the development of inhibitors of this complex and its enzymatic 
cofactors for childhood and infant AML.     
 
Epigenetic readers and chromatin-mediated signal transduction 
 
The bromodomain and extra terminal (BET) protein family member, BRD4, mediates 
cross talk between chromatin organisation and gene transcription. As epigenetic 
readers, BET proteins bind to acetylated lysine residues on histone tails where they 
can initiate chromatin-mediated signal transduction, carrying out normal or cancer 
dependent functions (Filippakopoulos & Knapp 2014; Filippakopoulos et al. 2012). In 
AML, BRD4 is thought to facilitate the aberrant expression of key oncogenes, such as 
c-Myc and BCL2, at a high level (Dawson et al. 2011; Zuber et al. 2011). BET 
inhibition is thought to block aberrant transcriptional elongation of these leukaemia-
relevant oncogenes, thereby preventing up regulation of leukaemic stem cell (LSC) 
self-renewal programmes and inducing differentiation (Zuber et al. 2011). BRD4 was 
identified by an RNA interference screen as a novel target in AML that is required for 
maintenance of MLL-leukaemia. BET inhibitors have demonstrated robust anti-
leukaemic effects in vitro and in vivo; across a range of AML cell lines, AML patient 
samples and in mouse model systems (Dawson et al. 2011; Zuber et al. 2011). 
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Interestingly, although BRD4 has been found at many enhancers genome wide, its 
residence at super enhancers is associated with co-occupancy with oncogenes, for 
example c-Myc. In addition, transcriptional elongation at super enhancers is more 
sensitive to BET inhibition, and gene expression of BRD4 targets from these sites is 
more selectively impaired (Lovén et al. 2013). Using BET inhibitors to target the 
addiction of tumour cells to high oncogene expression (Lovén et al. 2013), malignant 
cells could potentially be eliminated in a therapeutic window that spares normal 
hematopoietic cells (Lovén et al. 2013).
Childhood AML 
 
Table 1. Incidence of epigenetic gene mutations in AML by age 
 
Gene Mutation incidence in adult AML Mutation incidence in paediatric 
AML 
DNMT3A 20-22% (patients aged 18-81 years) 
(Yan et al. 2011; Ley et al. 2010)  
1-2% (patients aged <18 years) (Liang 
et al. 2013; Thol et al. 2011; Hollink 
et al. 2011)  
TET2 8-23% (patients aged 18-88 years) 
(Patel et al. 2012; The Cancer Genome 
Atlas Research Network 2013a; 
Metzeler, Maharry, et al. 2011)  
 
1.7% (patients aged <18 years)  
(Liang et al. 2013) 
ASXL1 3-17% (patients aged 18-100 years) 
(Patel et al. 2012; Boultwood et al. 
2010; Metzeler, Becker, et al. 2011; 
Schnittger et al. 2012)  
1-9% (patients aged <18 years)  
(Liang et al. 2013; Shiba et al. 2016).  
IDH1/2 5-33% (patients aged 18-88 years) (The 
Cancer Genome Atlas Research 
Network 2013a; Marcucci et al. 2010; 
Chou et al. 2010) 
1-4% (patients aged <18 years)  
(Valerio et al. 2014; Liang et al. 2013; 
Damm et al. 2011)  
EZH2 
 
 
 
 
1-5% (patients aged 18-88 years) (The 
Cancer Genome Atlas Research 
Network 2013a; X. Wang et al. 2013)  
Rare (patients aged 1-20 years)  
(Ernst et al. 2012) 
Much of the work into the epigenetics of AML has involved adult cohorts, but a small 
number of studies indicate epigenetic aberrations, although less common, may also 
play a role in paediatric AML. Table 1 summarises the frequency of epigenetic 
mutations in adult and childhood AML. Despite mutations in epigenetic regulators 
occurring less frequently in paediatric AML, an abnormal chromatin landscape 
appears to be a feature shared between both adult and paediatric AML; aberrant DNA 
methylation has been reported in paediatric patients (Rudenko et al. 2016); and 
hypermethylation of the GATA binding protein 4 (GATA4), a tumour suppressor, in 
primary paediatric AML samples (59/105 patients) (Tao 2015). In addition, aberrant 
p15 promoter methylation was reported in both adult and childhood AML (4/4 
paediatric patients) (Wong et al. 2000). Some paediatric AMLs may therefore be 
amenable to therapeutic targeting with novel epigenetic inhibitors.  
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Epigenetic therapies for adult AML and potential suitability for paediatric AML 
 
Figure 1. Epigenetic therapies in acute myeloid leukaemia. DNA methylation, 
histone modifications and associated epigenetic regulators. Epigenetic inhibitors are 
highlighted in red. C (cytosine), 5mC (5-methylcytosine), 5hmC (5-
hydroxymethylcytosine), 2KG (2-ketoglutarate), αKG (α-ketoglutarate), Ac 
(acetylation). 
 
Epigenetic modifications, unlike those of a genetic nature, are highly susceptible to 
modification and/or inhibition by specifically targeted small molecules (figure 1). 
These therapies are rapidly entering the clinic in the hope that cancer-dependent 
epigenetic aberrations can be targeted (Wouters & Delwel 2016). 
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Table 2. Epigenetic therapies in clinical trial for AML 
Epigenetic therapy  Target  Clinical trial 
(adult) 
Clinical trial 
(paediatric) 
Vorinostat (SAHA) Histone deacetylases Numerous NCT02083250, 
NCT01422499• 
NCT03263936 
Decitabine (5-aza-
2’deoxycytidine) 
DNA methyl 
transferases 
Numerous NCT03164057, 
NCT03263936, 
NCT03132454, 
NCT01177540* 
Azacitidine (5-
azacytidine) 
DNA methyl 
transferases 
Numerous NCT02450877, 
NCT01861002•, 
NCT02275665, 
NCT03164057 
Panabinostat Histone deacetylases Numerous NCT02676323 
Ivosidenib (AG-120) IDH1 mutations NCT02074839, 
NCT03245424  
NCT03245424 
FT-2102 IDH1 mutations NCT02719574 N/A 
Enasidenib (AG-221),  IDH2 mutations NCT02577406, 
NCT01915498  
N/A 
MK-8628-005 (formerly 
known as OTX015) 
BET-bromodomains NCT02698189 N/A 
CPI 0610 BET-bromodomains NCT02158858 N/A 
Pinometostat (EPZ 5676) DOTL1 NCT01684150•  NCT02141828• 
 
*Indicates trial has been completed 
 
Targeting DNA methylation  
 
DNMT inhibitors 
 
5-azacytidine (azacytidine) and 5-aza-2’-deoxycytidine (decitabine) are two 
hypomethylating agents that have been clinically approved by the Food and Drug 
Administration (FDA) for the treatment of myeloid malignancies, including AML. 
Both inhibit DNA methyl transferases and are hypothesised to have anti-cancer 
activity by reversing hypermethylation-associated silencing of tumour suppressors. 
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Recent studies have demonstrated clinical benefit with azacytidine (Dombret et al. 
2015; Fenaux et al. 2009), particularly in elderly patients who are ineligible for more 
intensive regimens. Although a direct link between hypomethylation and gene 
activation following azacytidine treatment has been demonstrated (Lund et al. 2014), 
precisely how this elicits AML cell killing is unknown, which makes patient 
stratification difficult. It is not mandatory to test for aberrant methylation patterns in 
patients as a pre-requisite for azacytidine treatment and the effectiveness of these 
agents in the absence of disordered methylation (for example in some paediatric 
patients) is unknown.  
 
A small retrospective analysis of 24 children with MDS reported good tolerability and 
clinical activity for azacytidine that included complete clinical remission in 1 patient 
and stable disease in 6 patients after azacytidine treatment  (EWOG-MDS Cseh et al 
2016). In another retrospective analysis, 8 paediatric patients with relapsed/refractory 
AML were treated with low-dose decitabine after failing multiple regimens and being 
ineligible for intensive chemotherapy (Phillips et al. 2013). 3 out of 8 patients showed 
a complete response with a favourable toxicity profile, suggesting promising clinical 
benefit in a high risk, heavily pretreated relapsed/refractory setting. Interestingly, the 
authors report a good response in children who subsequently received a 
haematopoietic stem cell transplant (HSCT); they hypothesised that demethylating 
treatments can relieve epigenetic silencing of tumour antigens, increasing their 
‘visibility’ to the immune system and enhancing the graft-versus-tumour effect 
(Sigalotti 2003; Phillips et al. 2013). A large phase 2 study testing azacytidine in 
children with relapsed AML patients <18 years is currently on-going (NCT02450877; 
see table 2). 
 
A pre-clinical study using paediatric AML cells both in vitro and in vivo demonstrated 
enhanced anti-leukaemic activity with decitabine and cytarabine compared with 
cytarabine alone (Leonard et al. 2014). However the clinical study in relapsed AML 
was suspended due to a lack of ‘significant clinical benefit’ (defined as response rate, 
duration of response, overall response, event-free survival and overall survival) 
(NCT01853228). A randomised phase 1 trial assessing induction chemotherapy with 
and without prior decitabine treatment in paediatric AML patients (aged 1- 16 years) 
demonstrated good tolerability and no unexpected side effects, although no difference 
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in complete remission rates was observed between the two treatment arms 
(NCT01177540). Given the small number of patients enrolled (25), further 
randomised trials are required to assess potential benefit of decitabine pre treatment 
for paediatric AML (Gore et al. 2017). Azacytidine is being tested in combination 
with other agents in adults with high risk or relapsed/refractory AML: Cytarabine and 
Mitoxantrone (NCT01839240); Mitoxantrone, Etoposide, and Cytarabine 
(NCT01249430) (Seval and Ozcan 2015). In the paediatric setting, a phase 1 trial 
testing azacytidine with fludarabine/cytarabine chemotherapy (NCT01861002) in 
children with relapsed or refractory AML has been completed, reporting good 
tolerability and clinical efficacy (complete remission achieved in 7 out of 12 (58%) 
AML patients) (Sun et al. 2018). Although a small number of patients were enrolled, 
the results of this trial are especially encouraging considering 8/12 (67%) of patients 
were refractory to ≥2 prior salvage treatment attempts, therefore the results of this and 
ongoing adult trials may encourage the use of novel combinations with azacytidine 
for paediatric AML.  
 
Relapse after a HSCT is a significant cause of mortality in paediatric AML and these 
patients can rarely be salvaged (van den Brink et al. 2010). For patients whose 
minimal residual disease indicates imminent relapse after HSCT, a study by 
Platzbecker et al (NCT00422890) showed that azacytidine can delay relapse by 6-12 
months, potentially ‘opening a window’ for patients until a second allogeneic HSCT 
is possible (Platzbecker et al. 2011).  
 
Further investigation is required to determine the utility of hypomethylating agents in 
the treatment of paediatric AML. Azacytidine might represent a life-extending option 
for children who have failed multiple regimens and are no longer eligible for more 
intensive treatments. Results from adult cohorts suggest limited efficacy as a single 
agent (Seval and Ozcan 2015); therefore the full potential of these agents may be 
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reached in combination with other targeted or chemotherapeutic treatment for young 
patients.  
 
 IDH 1/2 inhibitors 
 
Novel IDH inhibitors have been developed and are being tested in early phase clinical 
trials in adult cohorts, with promising clinical efficacy being reported. AG-120, an 
inhibitor of mutant IDH1 has demonstrated good clinical efficacy in a phase 1 trial in 
relapsed AML patients (>18 years old), with an overall response rate of 41% (52/125 
patients) (NCT02074839) (Stein & Tallman 2016). A phase 1/2 study of Enasidenib 
(AG-221), a selective inhibitor of mutant-IDH2 was tested in 176 relapsed/refractory 
AML patients harbouring IDH1/2 mutations (aged >18 years and > 60 years in 
separate cohorts) (NCT01915498). 40.3% of patients achieved a haematological 
response to Enasidenib, including complete remissions in 34 patients (19.3%). 11% of 
these patients went on to receive HSCT, suggesting IDH2 inhibition could be a bridge 
to curative treatments - an encouraging possibility in the relapsed/ refractory setting 
where therapeutic options are few (Stein et al. 2017).   
 
IDH1/2 mutations are strongly associated with cytogenetically normal AML in adults, 
and co-occur with different mutations depending on the IDH mutation. For example, 
mutations in IDH2R140, proposed by Papaemmanuil et al. as a distinct AML subgroup, 
show strong co-mutation with NPM1, whereas IDH2R172 are mutually exclusive with 
NPM1 mutations (K. P. Patel et al. 2011; Papaemmanuil et al. 2016). Although 
IDH1/2 mutations are less common in paediatric AML (see table 1), studies on 
paediatric patients with cytogenetically normal AML have reported higher 
frequencies of IDH1/2 mutations (10.8%) than in cohorts with patients harbouring 
various cytogenetics (Valerio et al. 2014; Damm et al. 2011b). Given that 10-25% of 
paediatric AML is cytogenetically normal (Bolouri et al. n.d.; Valerio et al. 2014), 
further research is warranted to test the utility of IDH1/2 inhibition in specific 
subgroups of paediatric patients that harbour mutations.  
 
Liang et al also found a strong association between IDH1/2 mutations and MLL-
leukaemias (Liang et al. 2013). Although the number was small, it was statistically 
significant and warrants further validation in larger cohorts of MLL-AML patients, 
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particularly given the frequency of MLL-AML in this age group (Liang et al. 2013). 
These leukaemias may be vulnerable to a combination strategy, targeting both IDH1/2 
mutations and the deregulated MLL-complex (with DOT1L inhibitors; see below) 
(Liang et al. 2013). This treatment strategy may be restricted to paediatric AML, as 
MLL-translocations and IDH1/2 mutations do not appear to co-occur in adult AML 
(Papaemmanuil et al. 2016). Studies have reported an association between IDH/2 and 
FLT3 mutations in both paediatric and adult AML, indicating that these mutations co-
operate in leukaemogenesis. Cells harbouring these mutations could be vulnerable to 
dual targeting with IDH and FLT3 inhibitors (Andersson et al. 2011; Papaemmanuil 
et al. 2016).  
 
Interestingly, recent work has highlighted that IDH1/2 mutations induce BCL-2 
dependency in AML (Wouters & Delwel 2016; Chan et al. 2015), raising the 
possibility that dual inhibition of BCL-2 and mutant IDH1/2 may be synthetically 
lethal in AML. Venetoclax is a BCL-2 inhibitor currently in clinical trials for both 
adult and paediatric AML (NCT02203773, NCT03236857 and NCT03194932). As 
discussed, IDH1/2 mutations are less frequent in childhood AML than adult, however 
a small subset of paediatric patients may benefit from inhibition of BCL-2 and 
IDH1/2.  
 
 
 
Targeting histone de-acetylation (HDAC inhibitors) 
 
In a similar manner to DNMT inhibitors, HDAC inhibitors may activate 
epigenetically silenced tumour suppressor genes and elicit cancer cell killing. HDAC 
inhibitors (via histone re-acetylation) enable accessibility of transcriptional machinery 
and downstream gene expression, inducing apoptosis in leukaemic blasts (Nebbioso et 
al. 2004). In addition to targeting histone acetylation, HDAC inhibitors can re-
acetylate other proteins with important roles in AML (such as p53), contributing to 
the anti-leukaemic effects of HDAC inhibition in a histone independent manner (Qi et 
al. 2015). HDAC inhibitors have been tested in clinical trials for adult AML patients, 
alone and in combination with chemotherapy and with variable efficacy (Stahl et al. 
2016). For example, Kuendgen et al reported only a 5% response rate in elderly AML 
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patients treated with valproic acid (a class I HDAC inhibitor) in combination with all-
trans retinoic acid (ATRA) (Kuendgen et al. 2006). A phase I study of vorinostat 
(suberoylanilide hydroxamic acid (SAHA)), a HDAC inhibitor, in 41 AML patients 
reported a 17 % response rate, including complete remission in 4 patients (Garcia-
Manero et al. 2007). However, further studies did not support a rationale for the use 
of HDAC inhibitors as a monotherapy in AML, leading to examination of HDAC 
inhibitors in combination with chemotherapy (reviewed in (Stahl et al. 2016). The 
combination of HDAC inhibitors and conventional cytotoxics has been well studied: 
Garcia-Manero et al reported an 85% overall response rate in AML patients treated 
with vorinostat combined with conventional chemotherapy (idarubicin and 
cytarabine), although other studies have reported more modest response rates. HDAC 
inhibitors have been tested alongside DNMT inhibitors, but despite promising in vitro 
data, clinical studies failed to demonstrate superiority of HDAC inhibitors with 
azacytidine over HDAC inhibition alone (Stahl et al. 2016). 
It would be important to know if paediatric AML is more vulnerable to HDAC 
inhibition than adult AML. Leukaemia-associated fusion proteins such as AML-ETO 
have been shown to block gene expression at key differentiation-gene loci via 
recruitment of HDACs (Wang et al. 1999; Kuendgen et al. 2006; Gelmetti et al. 1998) 
- importantly this repression is alleviated via HDAC inhibition, enabling 
differentiation of leukaemic blasts. Although clinical efficacy of HDAC inhibitors in 
adults has been limited, these fusions are more commonly associated with paediatric 
AML (Byrd 2002; Rubnitz et al. 2002; Grimwade et al. 1998), raising the possibility 
that paediatric patients may reap greater benefits of HDAC target therapies than adult 
counter-parts.   
HDAC inhibitors are now being tested in paediatric AML (see table 2). A phase 1 
trial of Panbinostat, a next generation HDAC inhibitor, in paediatric patients with 
haematological malignancies has been completed with results pending. Panobinostat 
is currently being tested in paediatric AML patients alongside chemotherapy 
(fludarabine and cytarabine) (NCT02676323). A phase I trial of Vorinostat is also 
underway in paediatric patients with relapsed leukaemias (NCT03263936). The 
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results of these trials will be the first steps in assessing utility of HDAC inhibitors for 
paediatric patients. 
 
Targeting MLL-leukaemias via H3K79 methylation (DOT1L inhibitors) 
 
Targeting vulnerabilities of MLL-associated leukaemias is a highly attractive 
treatment strategy in paediatric AML, where MLL translocations occur more 
frequently than in adult AML (30-50% versus >10%, respectively) (Chaudhury et al. 
2015; Krivtsov & Armstrong 2007; Schoch 2003; Grimwade et al. 1998). In addition, 
some MLL translocations are associated with high risk of relapse and poor prognosis 
in childhood leukaemias. For example, the translocation t(6;11)(q27;q23) confers a 
poor prognosis, with overall survival at 5 years 22%, highlighting the need for better 
therapies for these high-risk patient groups (Balgobind et al. 2011; Karol et al. 2014). 
Inhibition of DOT1L blocks MLL target gene expression, for example MEIS1 and 
HOXA9, and work in model systems has demonstrated a requirement for this histone 
methyl transferase (HMT) in MLL-associated leukaemias (Bernt et al. 2011; Daigle et 
al. 2013) (Bernt et al. 2011; Daigle et al. 2013) . 
 
A phase I trial using Pinometostat (EPZ-5676), a DOT1L inhibitor, was initiated in 
paediatric patients with relapsed/refractory AML harbouring MLL-gene 
rearrangements, but reported only transient reductions in leukaemic blast in 7/18 
patients (NCT02141828) (Shukla et al. 2016) – a disappointing outcome considering 
promising pre-clinical work. In the adult AML setting, objective response was 
achieved in 6 patients, including morphologic (1 patient) and cytogenetic (1 patient) 
complete remission, however recruitment to this trial was higher than in the paediatric 
study by Shukla et al (49 versus 18, respectively), therefore may not be directly 
comparable to the paediatric study (NCT01684150) (Stein et al. 2015). 
 
Whilst Pinometastat (EPZ-5676) lacks clinical benefit as a single agent, it would be 
interesting to test the utility of DOT1L along with conventional cytotoxic regimes for 
relapsed/refractory AML. Work by Liu et al (Liu et al. 2014) showed that inhibition 
of DOT1L sensitises MLL-leukaemia cells to chemotherapy through impaired DNA 
damage signalling, demonstrating enhanced killing of MLL- leukaemia cell lines and 
patient samples with DOT1L inhibitor compared to chemotherapy alone. This is an 
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encouraging finding given that some MLL-leukaemias are resistant to conventional 
cytotoxics, suggesting a potential window of therapeutic benefit where leukaemic 
blasts are sensitised to chemotherapy. Overexpression of FLT3 has been reported in 
MLL-AML, and EPZ-5676 combined with sorafenib (a FLT3 receptor inhibitor) 
achieved synergistic toxicity compared with EPZ-5676 alone (which had a very 
modest effect on cell viability as a single agent) (Lonetti et al. 2016). 
 
Given the high association of MLL gene rearrangements with paediatric AML, 
targeting this complex remains an attractive therapeutic strategy. Combination 
therapy, either with standard chemotherapy or by targeting of other components of the 
MLL-driven machinery, could be key for more potent disease-elimination and long-
term clinical benefits. Further pre-clinical work is warranted to elucidate 
vulnerabilities within MLL-complexes and identify synergistically toxic combinations 
alongside DOT1L inhibition in MLL-rearranged leukaemias. 
 
Targeting epigenetic readers (BET proteins) 
 
BET inhibitors are being tested in early phase clinical trials in adults with a range of 
solid and haematological malignancies. OTX015, a BET-bromodomain inhibitor, was 
associated with anti-leukaemic activity in patients with advanced AML (response 
rate: 5/28 patients) who had failed conventional therapies (NCT01713582) (Dombret 
et al. 2014). A clinical trial using CPI0610, an additional BET-bromodomain 
inhibitor, is underway in previously treated acute leukaemia and myelodysplastic 
syndrome patients (NCT02158858; see table 2). Much of the preclinical work 
demonstrating efficacy of BET inhibitors in AML used the MLL-AF9 model, which 
is thought to be extremely sensitive to BET inhibition (Dawson et al. 2011; Zuber et 
al. 2011). Given the association between MLL-leukaemia and paediatric AML, there 
is a rationale to use BET inhibitors for childhood AML. In addition, BET inhibitors 
may potentiate the effects of other targeted therapies. For example, BET inhibitors 
down regulate BCL-2 expression and anti-apoptotic function, and BCL-2 inhibitors 
(for example venetoclax) are currently in clinical trials for paediatric AML patients 
(NCT032368570). It could be hypothesised that drug synergy may be achieved with 
dual targeting of BET and BCL-2. This could be an attractive approach in AML by 
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targeting oncogenes (such as c-Myc) while simultaneously inducing apoptosis through 
BCL-2 inhibition. 
. 
Combining epigenetic and immunotherapy in paediatric AML  
Immunotherapy, including antibodies against AML cell surface proteins and chimeric 
antigen receptor engineered (CAR-T) cell therapy, is a promising area of therapy for 
childhood AML (Tasian 2014). CD33 is a trans-membrane receptor protein which is 
expressed on both adult and paediatric AML blasts and is associated with poor 
prognosis when expressed at a high level in AML (Tasian 2014; Pollard et al. 2012; 
R. B. Walter et al. 2007). An anti-CD33 monoclonal antibody/calicheamicin 
conjugate, gemtuzumab ozogamicin (GO), was withdrawn from the market due to 
concerns over increased mortality, but has regained favour after a number of positive 
publications and has since been reintroduced (Gamis et al. 2014; Pollard et al. 2016; 
Castaigne et al. 2012). New dosing regimens with improved toxicity outcomes have 
encouraged further evaluation of GO in adult and paediatric AML (Laing et al. 2017). 
GO has been tested in paediatric AML as a single agent with good outcomes 
(remission rates of 28-54%) (Tasian 2014; Satwani et al. 2012; Zwaan et al. 2010; D. 
Reinhardt et al. 2004), and is currently being tested using a fractionated dosing 
regimen in an international phase 3 randomised trial, Myechild01, where it is given in 
combination with induction chemotherapy (NCT02724163). Interestingly, azacytidine 
treatment enhanced the anti-leukaemia activity of an alternative anti-CD33 antibody-
drug conjugate, SGN-CD33, in vivo (Sutherland et al. 2011). Although clinical testing 
of SGN-CD33A has been suspended due to increased mortality in a phase 3 trial, 
demethylation and re-expression of CD33 and natural killer cell enzymes is the 
proposed mechanism of drug synergy, therefore it is predicted that this combination 
approach may to be applicable to alternative anti-CD33 agents (and not specific to 
SGN-CD33). This approach may hold great promise in paediatric AML given that 
approximately 80% express CD33 (Tasian 2014). Similarly, demethylating agents 
(via a similar mechanism) may potentiate the effects of CAR-T cell therapy in 
paediatric AML patients. CAR-T cells are genetically engineered to target tumour 
antigens and therefore increased expression of tumour antigens via demethylating 
agents might elicit synergistic killing of AML cells (Tasian 2014). In addition, IDH 
mutations give rise to tumour-specific neoantigens that CAR-T cells could be 
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engineered to target; IDH1/2 inhibitors could therefore be used in combination with 
CAR-T therapy to target IDH1/2 mutant AML (Wouters & Delwel 2016; Schumacher 
et al. 2014). Intuitively this strategy may be more appropriate for adult AML, where 
IDH mutations occur more frequently than in children (see table 1). However, given 
the higher incidence of IDH mutations in cytogenetically normal paediatric AML 
compared to those with cytogenetic abnormalities (10.8%) (Valerio et al. 2014), 
appropriate patient stratification may identify subgroups of paediatric patients who 
are sensitive to CAR-T therapy against IDH mutant AML.  
 
Demethylating agents may also have an important role alongside immune checkpoint 
inhibitors in AML therapy. Immune checkpoint receptors, such as programed cell 
death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), 
are expressed on T cells and suppress anti-tumour immunity. Immune checkpoint 
inhibitors (monoclonal antibodies) targeting CTLA-4 or PD-1/PD-1 ligand (PD-1L), 
reverse T cell inhibition and enable AML cell killing. A number of clinical trials with 
checkpoint inhibitors have been initiated in AML patients and are summarised in 
Lichtenegger et al 2017 (Lichtenegger et al. 2017)). Azacytidine treatment has been 
shown to upregulate PD-1 expression in T cells of AML patients, preventing an 
effective immune response to the leukaemic blasts and potentially leading to therapy 
resistance (Ørskov et al. 2015). Trials combining immune checkpoint inhibitors with 
azacytidine are under way for adults with AML, including azacytidine with PD-1 
inhibitor nivolumab (NCT02397720), azacytidine with or without PD-1L inhibitor 
durvalumab (NCT02775903) and azacytidine with or without PD-1L inhibitor 
atezolizumab (NCT02508870). In the phase 1 trial of azacytidine with nivolumab, an 
overall response rate of 35% was achieved (including 6 complete remissions), which 
compares favourably to historical survival outcomes with azacytidine alone (Daver et 
al. 2017). Nivolumab is to be tested as a single agent in paediatric AML patients. 
Given that azacytidine is already being tested in children with AML, promising 
results from trials using azacytidine and immune checkpoint inhibitors in adults may 
encourage clinical assessment of this therapeutic strategy in paediatric AML.  
 
Clonal haematopoiesis with indeterminate potential 
Genetic mutations can be used to map the evolutionary trajectory of cancer in an 
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individual patient (Yates & Campbell 2012). Conversely, the presence of ancestral 
mutations in apparently healthy individuals can indicate an increased risk of cancer 
development. Clonal haematopoiesis (CH), or clonal haematopoiesis with 
indeterminate potential (CHIP) arises when a mutation imparts a growth advantage on 
a HSC, leading to expansion of the dominant clone and skewed haematopoiesis. 
Although not a new concept with skewed X-inactivation patterns in elderly females 
being reported in the 1990s (Champion et al. 1997; Busque et al. 1996), next 
generation sequencing has recently increased our understanding of this pre-leukaemic 
state. Expanded clones harbour epigenetic gene mutations commonly observed in 
AML, such as DNMT3a, TET2 and ASXL1, and indeed are associated with an 
increased risk of haematological malignancy (Genovese et al. 2014; Jaiswal et al. 
2014). Why mutations in clonal haematopoiesis are so commonly found in epigenetic 
regulators is not known, but this new era of epigenetic therapy brings hope that this 
pre-leukaemic reservoir could be eradicated before malignant transformation (Shlush 
et al. 2014). 
It is widely accepted that clonal haematopoiesis is rare in childhood. However, 
sequencing efforts comparable to that done in adults are lacking in younger subjects. 
As mentioned, mutations in epigenetic machinery, although rare, do exist in paediatric 
AML. It is reasonable to hypothesise that these mutations existed as a dormant clone 
that later initiated the leukaemia, raising the possibility that these cancers may also be 
vulnerable to epigenetic targeting. In a case study of a paediatric AML patient (13 
years old), a pre-leukaemic clone harbouring a DNMT3a mutation was identified. The 
mutant clone persisted during remission, indicating therapy resistance and 
highlighting the existence of CHIP in childhood (Göhring et al. 2016). Given the 
rarity of CHIP-associated epigenetic mutations in paediatric AML, they are not 
usually studied at diagnosis (Göhring et al. 2016); it could be speculated therefore that 
CHIP is more prevalent in a subgroup of paediatric patients -  for example 
cytogenetically normal populations – than we currently appreciate.  
Despite the association between CHIP and leukaemia, its precise clinical relevance to 
AML, once established, is unknown. Curiously, recent work suggests that CHIP is not 
indicative of outcome (duration of remission or overall survival), despite these 
mutations persisting after therapy and being detected in the relapse clone (Gaidzik et 
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al. 2017). It would be useful to correlate this with response to epigenetic therapies. It 
is important therefore to address the possibility that children with AML, although 
often lacking CHIP and epigenetic mutations, may also benefit from targeted 
epigenetic therapy. If CHIP lacks prognostic relevance, the absence of CHIP in 
childhood needn't be a barrier to testing epigenetic drugs and warrants further 
investigation. Lastly, the use of error-corrected sequencing (ECS) enables better 
detection of rare allelic variants than NGS (Young et al. 2015). Exploiting this 
technology, Young et al report a 95% incidence of clonal haematopoiesis in 50-60 
year olds – much higher than was proposed in seminal papers from Genovese et al; 
and Jaiswal et al (Young et al. 2016). This work suggests that clonal haematopoiesis 
is almost ubiquitous by middle age, and progression to AML is exceptionally rare. 
Therefore, the significance of CHIP in leukaemia management, particularly 
concerning the use of epigenetic therapies, remains to be elucidated in both adult 
and paediatric cohorts.  
 
Conclusion  
 
There remains an urgent need for better therapies for both adult and paediatric AML. 
Epigenetic therapies have demonstrated clinical efficacy in adult AML, which is 
associated with abnormalities to the epigenome. The low frequency of epigenetic 
abnormalities in paediatric AML is not a reason to limit the use of epigenetic 
therapies to adult AML patients; there is evidence that epigenetic therapies may 
benefit children with the appropriate target. Although results from some trials of 
conventional chemotherapy for children with relapsed AML have had more 
favourable outcomes (summarised in (Kaspers 2014)) than the epigenetic therapies 
detailed in this review, in these early stages of testing epigenetic therapy in paediatric 
AML it is important to consider that moving towards more ‘personalised’ medicine 
will require evaluation of targeted therapies that may only demonstrate clinical benefit 
after appropriate patient stratification. In addition, it is unlikely that one drug – 
epigenetic or otherwise – will be curative in AML due to the clonal heterogeneity 
which provides reservoirs for drug resistance and subsequent relapse; it is possible 
that dual targeting of synthetic lethal pathways can yield greater cell kill in AML and 
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transform the outcomes for paediatric AML patients. For these reasons, further 
research into drug combinations that utilise epigenetic therapies is warranted. 
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